Ioversol
Chemical compound
- AU: B1
- V08AB07 (WHO)
- AU: Unscheduled
- US: WARNING[1]
- 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
- 87771-40-2
Y
- 3741
- DB09134
Y
- 3610
N
- N3RIB7X24K
- D01555
Y
- ChEMBL1200614
N
- DTXSID2045521
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO
- InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
N
- Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.[2][3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
- ^ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.
- v
- t
- e
Iodinated, Water soluble |
| ||||||
---|---|---|---|---|---|---|---|
Iodinated, Water insoluble |
| ||||||
Non-iodinated |
Paramagnetic | |
---|---|
Superparamagnetic |
|
Other |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e